Vabysmo

Eylea

Pharma

Regeneron sees more regulatory issues, sales declines for Eylea

As regulatory delays continue to plague Regeneron's Eylea, quarterly sales for the treatment have dropped below $1B for the first time since 2018.

Kevin Dunleavy Apr 29, 2026 12:05pm

Metallic arrow symbols which are illuminated by blue and magenta lights merge on blue and magenta b

Ligand lays out $739M for royalty aggregator compatriot Xoma

Apr 27, 2026 10:19am

Roche

UPDATED: Roche Q1 earnings see hits and misses across key products

Apr 24, 2026 1:55pm

All Eyes on DME campaign

Genentech taps Damon Wayans for ‘All Eyes on DME’ campaign

Apr 24, 2026 8:57am

Regeneron

Regeneron faces category headwinds for eye disease drug Eylea

Jan 30, 2026 11:41am

Graham

Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop

Jan 29, 2026 11:23am